Vaccine exhibit notable competence against Rotavirus

Vaccine exhibit competence against Rotavirus

A study published in the journal Vaccine shows that The Serum Institute of India Pvt. Ltd.’s rotavirus vaccine BRV-PV (known as ROTASIIL) is effective against Rotavirus. The vaccine is safe and gives notable potency against severe rotavirus gastroenteritis.

According to Wikipedia, Rotavirus is the most common cause of diarrhoeal disease among infants and young children. It is a genus of double-stranded RNA viruses in the family Reoviridae. Nearly every child in the world is infected with rotavirus at least once by the age of five. The virus is transmitted by the faecal-oral route. It affects and damages the cells that line the small intestine and causes gastroenteritis(which is often called “stomach flu” despite having no relation to influenza).

In 2013, Accounted 47,100 deaths occurred in India because of rotavirus, which is nearly 22 percent of all rotavirus deaths that happened all over the world. ROTASIIL has been a vaccine which can protect from the deadly virus. The virus which causes the risks like dehydration, hospitalisations, and deaths.

Dr Rajeev Dhere, executive director of the Serum Institute, whose leadership led to the development of this vaccine, said that they are overjoyed with the results of the vaccine, which demonstrate that ROTASIIL could save the lives of thousands of children each year in India and, potentially, around the world also.

An order for 3.8 million doses of ROTASIIL is placed by the Government of India. So the authorities can use the vaccine in the Universal Immunization Programme, which serves nearly 26 million children.

Serum Institute has produced the vaccine doses and is waiting for the instructions from the Ministry of Health and Family Welfare for the distribution. People also can buy ROTASIIL in India’s private market at the end of this year.

The ROTASIIL vaccine which used in the Niger study was stored at less than 25°C and brought for vaccination at medium temperature, thus avoiding the typically challenging and expensive cold-chain requirements that apply to most other vaccines. The ROTASIIL used in the India study was from the same batches of vaccine practised in the Niger study.

About the author

Megha Singh

A news media professional with a strong experience in online journalism, content management, and social media. Megha’s strength includes the sound knowledge of health, yoga, meditation, and proficiency in packaging content for health-related issues.

Add Comment

Click here to post a comment

You Might Also Like